<DOC>
	<DOCNO>NCT02911324</DOCNO>
	<brief_summary>The purpose pilot research study test effect medication call nabilone ( Cesamet ) adults obsessive-compulsive disorder ( OCD ) . Participants receive either nabilone , nabilone combination form cognitive-behavioral therapy ( CBT ) call exposure response prevention ( EX/RP ) . Nabilone synthetic cannabinoid act brain 's `` endocannabinoid system , '' hypothesize play role OCD . Nabilone approve FDA treatment chemotherapy-induced nausea vomit . It FDA-approved treat OCD .</brief_summary>
	<brief_title>Cannabinoid Medication Adults With OCD</brief_title>
	<detailed_description />
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Nabilone</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Age 1860 Physically healthy , pregnant Primary OCD Patient psychotropic ( except selective SRIs ) type drug likely interact nabilone Ability provide inform consent Ability tolerate treatment freeperiod History significant medical condition may increase risk participation Females pregnant nursing Current lifetime history psychiatric disorder OCD may increase risk participation ( e.g . lifetime psychosis bipolar disorder ) Current substance use disorder positive urine toxicology screening , adverse reaction cannabinoid Patients already receive EX/RP</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>